Dermatomyositis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc

DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Forecast
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Dermatomyositis Market Report:
• The Dermatomyositis market size was valued approximately USD 230 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2019-2032).
• In July 2024, Priovant Therapeutics announced that it had completed enrollment for the Phase 3 VALOR study assessing brepocitinib in dermatomyositis. This study has included 241 participants from 90 locations across four continents, marking it as the largest interventional trial for dermatomyositis ever undertaken.
• In the US, the highest incidence of cases occurred within the 40-59 age bracket, followed by the 60-79, 18-39, and 0-17 age brackets. Conversely, the lowest incidence was observed in the ≥80 age group, with approximately 14,600, 13,000, 5,000, 4,000, and 1,500 cases, respectively, in 2023.
• DelveInsight's estimates indicate that among EU4 and the UK, Germany held the largest market share for dermatomyositis, reaching nearly USD 15 million in 2023, followed by the UK with almost USD 13 million in the same year. Conversely, Spain had the smallest market share, totaling around USD 9 million.
• As per DelveInsight's assessment, the total diagnosed prevalent cases of dermatomyositis in the 7MM were roughly 71,000 in 2023. These numbers are projected to rise over the forecast period from 2024 to 2032.
• In 2023, the US had the highest number of diagnosed prevalent cases of dermatomyositis among the 7MM, totaling approximately 38,000 cases, followed by Japan with nearly 12,000 cases.
• In 2023, the age-specific diagnosed prevalent cases of dermatomyositis showed the highest numbers in the 40─59 and 60─79 age groups, with approximately 25,000 cases in each group among the 7MM.
• In the US, the highest number of cases were observed in the 40-59 age group, followed by the 60-79, 18-39, and 0-17 age groups, while the lowest number of cases were reported for the ≥80 age group. Specifically, there were nearly 14,600, 13,000, 5,000, 4,000, and 1,500 cases, respectively, in 2023.
• Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
• Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others
• The Dermatomyositis epidemiology based on gender analyzed that dermatomyositis is more common in women than in men (2:1)
• The Dermatomyositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dermatomyositis pipeline products will significantly revolutionize the Dermatomyositis market dynamics.

Dermatomyositis Overview
Dermatomyositis is a rare inflammatory muscle disease characterized by muscle weakness and skin rash. It is an autoimmune condition, meaning the body's immune system mistakenly attacks its own tissues, resulting in inflammation and damage to the muscles and skin. The hallmark symptom of dermatomyositis is a distinctive skin rash, which often appears as reddish or purplish patches, usually on the face, neck, shoulders, upper chest, and back.

Get a Free sample for the Dermatomyositis Market Report:
https://www.delveinsight.com/report-store/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dermatomyositis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dermatomyositis Epidemiology Segmentation:
The Dermatomyositis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Dermatomyositis
• Prevalent Cases of Dermatomyositis by severity
• Gender-specific Prevalence of Dermatomyositis
• Diagnosed Cases of Episodic and Chronic Dermatomyositis

Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dermatomyositis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomyositis market or expected to get launched during the study period. The analysis covers Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dermatomyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dermatomyositis Therapies and Key Companies
• Brepocitinib: Priovant Therapeutics, Inc.
• Lenabasum: Corbus Pharmaceuticals
• HIZENTRA: CSL Behring
• Ravulizumab: Alexion
• Lenabasum: Corbus Pharmaceuticals Inc.
• IMO-8400: Idera Pharmaceuticals
• GLPG3667: Galapagos NV
• M5049: EMD Serono
• human immunoglobulin G: CSL Behring
• PF-06823859: Pfizer
• Octagam: Octapharma
• KZR-616: Kezar Life Sciences, Inc.
• GB-0998: Japan Blood Products Organization
• H.P. Acthar Gel: Mallinckrodt
• Adrenocorticotropic Hormone Gel: Mallinckrodt
• tocilizumab: Genentech, Inc.
• Tacrolimus: Astellas Pharma Inc
• Rituximab: Biogen

Discover more about therapies set to grab major Dermatomyositis market share @ Dermatomyositis Treatment Market
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dermatomyositis Market Strengths
• A significant increase in knowledge and understanding of disease pathogenesis has led to the identification of various novel MoAstargeting C5 complement, IFNβ1, FcRn, and others.
• Established diagnostic and clinical guidelines for adult and juvenile dermatomyositis enable informed treatment and management of patients

Dermatomyositis Market Opportunities
• Better prognostic markers would allow physicians to diagnose and begin treatment at early onset, possibly preventing disease progression.
• The lack of curative and effective therapies allows pharma players to conduct trials and bring novel, disease-modifying therapies.

Scope of the Dermatomyositis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
• Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others
• Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement

To know more about Dermatomyositis companies working in the treatment market, visit @ Dermatomyositis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dermatomyositis Market Report Introduction
2. Executive Summary for Dermatomyositis
3. SWOT analysis of Dermatomyositis
4. Dermatomyositis Patient Share (%) Overview at a Glance
5. Dermatomyositis Market Overview at a Glance
6. Dermatomyositis Disease Background and Overview
7. Dermatomyositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Dermatomyositis
9. Dermatomyositis Current Treatment and Medical Practices
10. Dermatomyositis Unmet Needs
11. Dermatomyositis Emerging Therapies
12. Dermatomyositis Market Outlook
13. Country-Wise Dermatomyositis Market Analysis (2019-2032)
14. Dermatomyositis Market Access and Reimbursement of Therapies
15. Dermatomyositis Market Drivers
16. Dermatomyositis Market Barriers
17. Dermatomyositis Appendix
18. Dermatomyositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Dermatomyositis Pipeline https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Dermatomyositis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dermatomyositis market. A detailed picture of the Dermatomyositis pipeline landscape is provided, which includes the disease overview and Dermatomyositis treatment guidelines.

Dermatomyositis Epidemiology https://www.delveinsight.com/report-store/dermatomyositis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dermatomyositis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Dermatomyositis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Undifferentiated Pleomorphic Sarcoma, historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.